Milestone Pharmaceuticals’ (MIST) “Buy” Rating Reiterated at HC Wainwright

Milestone Pharmaceuticals (NASDAQ:MIST)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They currently have a $25.00 price target on the stock.

Milestone Pharmaceuticals Stock Performance

Shares of MIST stock opened at $2.05 on Monday. The company has a market cap of $109.33 million, a P/E ratio of -2.53 and a beta of 1.78. The business has a 50 day moving average of $1.96 and a two-hundred day moving average of $1.66. Milestone Pharmaceuticals has a 52 week low of $1.12 and a 52 week high of $2.75. The company has a quick ratio of 15.40, a current ratio of 15.40 and a debt-to-equity ratio of 2.18.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. As a group, analysts anticipate that Milestone Pharmaceuticals will post -0.62 EPS for the current year.

Institutional Investors Weigh In On Milestone Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the business. Valeo Financial Advisors LLC increased its position in Milestone Pharmaceuticals by 100.0% in the 3rd quarter. Valeo Financial Advisors LLC now owns 20,000 shares of the company’s stock valued at $30,000 after acquiring an additional 10,000 shares during the period. Atria Investments Inc increased its holdings in shares of Milestone Pharmaceuticals by 44.4% during the third quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock valued at $61,000 after purchasing an additional 12,430 shares during the period. PVG Asset Management Corp bought a new stake in shares of Milestone Pharmaceuticals during the third quarter valued at about $46,000. Finally, BML Capital Management LLC lifted its holdings in Milestone Pharmaceuticals by 3.0% in the third quarter. BML Capital Management LLC now owns 1,136,091 shares of the company’s stock worth $1,727,000 after purchasing an additional 33,196 shares during the period. Institutional investors own 86.18% of the company’s stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.